Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Buy Rating from HC Wainwright

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $10.00 price target on the stock.

Other research analysts also recently issued reports about the stock. Wells Fargo & Company cut their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Wedbush reissued a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, March 28th. Finally, UBS Group reduced their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Zentalis Pharmaceuticals presently has an average rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Stock Performance

NASDAQ:ZNTL opened at $1.26 on Thursday. The business’s fifty day moving average is $1.44 and its 200 day moving average is $2.33. The firm has a market cap of $90.66 million, a price-to-earnings ratio of -0.51 and a beta of 1.81. Zentalis Pharmaceuticals has a 52-week low of $1.01 and a 52-week high of $13.00.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, meeting the consensus estimate of ($0.67). Equities analysts predict that Zentalis Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Insider Transactions at Zentalis Pharmaceuticals

In other news, Director Scott Dunseth Myers bought 21,000 shares of the business’s stock in a transaction on Wednesday, April 30th. The stock was acquired at an average price of $1.40 per share, with a total value of $29,400.00. Following the completion of the purchase, the director now directly owns 281,192 shares in the company, valued at $393,668.80. This represents a 8.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 1.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ZNTL. Corton Capital Inc. purchased a new stake in Zentalis Pharmaceuticals during the fourth quarter valued at about $32,000. Captrust Financial Advisors bought a new position in shares of Zentalis Pharmaceuticals in the fourth quarter worth approximately $33,000. Prudential Financial Inc. bought a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at $39,000. Cerity Partners LLC purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at $40,000. Finally, Vident Advisory LLC bought a new position in shares of Zentalis Pharmaceuticals during the fourth quarter valued at about $45,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.